Tenax Therapeutics (NASDAQ:TENX) Given Buy Rating at Chardan Capital

Posted by Stanley Muller on Jul 2nd, 2026

Tenax Therapeutics (NASDAQ:TENX – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a research note issued on Thursday,Benzinga reports. They presently have a $27.00 target price on the specialty pharmaceutical company’s stock. Chardan Capital’s target price would indicate a potential upside of 103.16% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $35.00 price objective on shares of Tenax Therapeutics in a research note on Wednesday, June 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenax Therapeutics in a research report on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a report on Tuesday, March 10th. Piper Sandler lifted their price objective on Tenax Therapeutics from $20.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, June 12th. Finally, Lifesci Capital upgraded Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Tenax Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $38.00.

View Our Latest Analysis on Tenax Therapeutics

Tenax Therapeutics Trading Down 8.7%

Tenax Therapeutics stock opened at $13.29 on Thursday. Tenax Therapeutics has a 1-year low of $5.67 and a 1-year high of $18.38. The firm’s fifty day simple moving average is $12.26 and its 200-day simple moving average is $13.05. The company has a market capitalization of $352.45 million, a P/E ratio of -9.49 and a beta of 0.91.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The specialty pharmaceutical company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. On average, equities research analysts predict that Tenax Therapeutics will post -1.51 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Boothbay Fund Management LLC purchased a new position in Tenax Therapeutics in the 3rd quarter worth approximately $2,680,000. Persistent Asset Partners Ltd bought a new stake in shares of Tenax Therapeutics during the 4th quarter worth $796,000. Woodline Partners LP purchased a new position in Tenax Therapeutics in the third quarter worth $671,000. Citadel Advisors LLC increased its stake in Tenax Therapeutics by 318.1% in the third quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company’s stock valued at $329,000 after acquiring an additional 32,908 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new position in Tenax Therapeutics in the fourth quarter valued at $273,000. 1.67% of the stock is owned by institutional investors and hedge funds.

About Tenax Therapeutics

(Get Free Report)

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.